AstraZeneca is acquiring TeneoTwo, which is developing TNB-486 to treat relapsed and refractory B-cell non-Hodgkin's lymphoma. AstraZeneca will pay an upfront payment of $100 million and will pay up to $805 million more when certain development milestones are reached and up to $360 million when certain sales levels are reached. The deal is scheduled to close in Q3 2022.
AstraZeneca is acquiring TeneoTwo, which is developing TNB-486 to treat relapsed and refractory B-cell non-Hodgkin's lymphoma. AstraZeneca will pay an upfront payment of $100 million and will pay up to $805 million more when certain development milestones are reached and up to $360 million when certain sales levels are reached. The deal is scheduled to close in Q3 2022. 
astrazeneca.com
English (US) 